Performance analysis of Matinas Biopharma (MTNB)
Annual Return
Over the past 3 years, MTNB has had an average annual return of -65.94%, underperforming the benchmark SPY, which returned +22.77% annual.
Over the past 5 years, MTNB has had an average annual return of -54.70%, underperforming the benchmark SPY, which returned +14% annual.
Over the past 10 years, MTNB has had an average annual return of -30.82%, underperforming the benchmark SPY, which returned +15.53% annual.
Since Aug 18, 2014, MTNB has had an average annual return of -28.28%, underperforming the benchmark SPY, which returned +14.01% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +34.69% | +14.84% | -95.26% | -56.75% | -50.50% | -25.74% | -40.09% | +281.49% | -48.70% | -17.14% | +64.71% | +88.89% |
| 2014 | |||||||||||
| -43.75% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.36% | +2.01% | -17.76% | +30.40% | +24.54% | -2.46% | +34.69% | ||||||
| 2025 | +13.28% | +0% | -10.34% | +13.85% | +37.84% | +9.31% | -1.35% | +106.82% | +3.96% | -27.06% | -45.51% | -21.81% | +14.84% |
| 2024 | -7.51% | +40.04% | -3.23% | -31.49% | -11.85% | -3.27% | +1.87% | -42.16% | -24.10% | -82.49% | +3.87% | -20.50% | -95.26% |
| 2023 | +15.30% | -16.74% | -2.08% | +21.50% | -32.91% | -6.03% | -2.78% | -48.57% | -27.78% | +68.80% | -4.34% | +3.01% | -56.75% |
| 2022 | -25.74% | -23.43% | +40.08% | -12.35% | +1.43% | +10.47% | +11.39% | -19.32% | -10.42% | +22.64% | -15.38% | -24.24% | -50.50% |
| 2021 | +7.35% | -17.12% | -13.22% | -16.19% | -12.50% | +0.63% | -8.85% | +13.41% | +62.29% | -14.62% | -5.41% | -3.81% | -25.74% |
| 2020 | -40.53% | -25.93% | -40.00% | +28.17% | +17.03% | -14.11% | +1.15% | +0.02% | -2.06% | +5.22% | +32.75% | +27.10% | -40.09% |
| 2019 | +84.86% | +22.73% | -19.26% | -10.55% | -1.54% | -10.72% | -5.37% | -14.68% | -8.81% | +42.62% | +36.67% | +84.55% | +281.49% |
| 2018 | -15.52% | +0.92% | -22.65% | -42.09% | +26.63% | -22.64% | -18.65% | +30.30% | +100% | -20.65% | +15.62% | -29.50% | -48.70% |
| 2017 | +78.57% | +49.60% | -25.94% | -1.44% | -15.38% | -26.84% | -33.73% | +14.29% | +3.13% | -15.15% | +25.89% | -17.73% | -17.14% |
Drawdown analysis of Matinas Biopharma (MTNB)
The maximum drawdown for the MTNB was -99.75%, occurring on Apr 8, 2026. This drawdown has not yet recovered.
The current MTNB drawdown is -99.59%.
Since Aug 18, 2014 MTNB has experienced the following drawdowns:
- 50% or more: 3 times
- 40% or more: 3 times
- 30% or more: 4 times
- 20% or more: 5 times
- 10% or more: 8 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.75% | Mar 6, 2017 | 2285 | Apr 8, 2026 | Ongoing | Ongoing | Ongoing |
| -68.66% | Jun 5, 2015 | 177 | Feb 19, 2016 | 148 | Sep 20, 2016 | 325 |
| -62.77% | Sep 30, 2014 | 72 | Jan 13, 2015 | 59 | Apr 9, 2015 | 131 |
| -35.90% | Oct 5, 2016 | 54 | Dec 21, 2016 | 18 | Jan 19, 2017 | 72 |
| -29.45% | Apr 23, 2015 | 16 | May 15, 2015 | 13 | Jun 4, 2015 | 29 |
| -15.07% | Feb 14, 2017 | 2 | Feb 16, 2017 | 6 | Feb 27, 2017 | 8 |
| -11.76% | Apr 10, 2015 | 1 | Apr 13, 2015 | 8 | Apr 23, 2015 | 9 |
| -11.56% | Sep 22, 2016 | 2 | Sep 26, 2016 | 7 | Oct 5, 2016 | 9 |
| -5.88% | Sep 3, 2014 | 8 | Sep 19, 2014 | 7 | Sep 30, 2014 | 15 |
| -1.99% | Jan 23, 2017 | 1 | Jan 24, 2017 | 2 | Jan 26, 2017 | 3 |
| -1.56% | Mar 2, 2017 | 1 | Mar 3, 2017 | 1 | Mar 6, 2017 | 2 |
| -1.54% | Feb 2, 2017 | 1 | Feb 3, 2017 | 3 | Feb 8, 2017 | 4 |